Cargando…

Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice

Muscle repair in dysferlinopathies is defective. Although macrophage (Mø)-rich infiltrates are prominent in damaged skeletal muscles of patients with dysferlinopathy, the contribution of the immune system to the disease pathology remains to be fully explored. Numbers of both pro-inflammatory M1 Mø a...

Descripción completa

Detalles Bibliográficos
Autores principales: Farini, A., Tripodi, L., Villa, C., Napolitano, F., Strati, F., Molinaro, D., Facciotti, F., Cassani, B., Torrente, Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675822/
https://www.ncbi.nlm.nih.gov/pubmed/36402750
http://dx.doi.org/10.1038/s41419-022-05416-1
_version_ 1784833455696117760
author Farini, A.
Tripodi, L.
Villa, C.
Napolitano, F.
Strati, F.
Molinaro, D.
Facciotti, F.
Cassani, B.
Torrente, Y.
author_facet Farini, A.
Tripodi, L.
Villa, C.
Napolitano, F.
Strati, F.
Molinaro, D.
Facciotti, F.
Cassani, B.
Torrente, Y.
author_sort Farini, A.
collection PubMed
description Muscle repair in dysferlinopathies is defective. Although macrophage (Mø)-rich infiltrates are prominent in damaged skeletal muscles of patients with dysferlinopathy, the contribution of the immune system to the disease pathology remains to be fully explored. Numbers of both pro-inflammatory M1 Mø and effector T cells are increased in muscle of dysferlin-deficient BlAJ mice. In addition, symptomatic BlAJ mice have increased muscle production of immunoproteasome. In vitro analyses using bone marrow-derived Mø of BlAJ mice show that immunoproteasome inhibition results in C3aR1 and C5aR1 downregulation and upregulation of M2-associated signaling. Administration of immunoproteasome inhibitor ONX-0914 to BlAJ mice rescues muscle function by reducing muscle infiltrates and fibro-adipogenesis. These findings reveal an important role of immunoproteasome in the progression of muscular dystrophy in BlAJ mouse and suggest that inhibition of immunoproteasome may produce therapeutic benefit in dysferlinopathy.
format Online
Article
Text
id pubmed-9675822
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-96758222022-11-21 Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice Farini, A. Tripodi, L. Villa, C. Napolitano, F. Strati, F. Molinaro, D. Facciotti, F. Cassani, B. Torrente, Y. Cell Death Dis Article Muscle repair in dysferlinopathies is defective. Although macrophage (Mø)-rich infiltrates are prominent in damaged skeletal muscles of patients with dysferlinopathy, the contribution of the immune system to the disease pathology remains to be fully explored. Numbers of both pro-inflammatory M1 Mø and effector T cells are increased in muscle of dysferlin-deficient BlAJ mice. In addition, symptomatic BlAJ mice have increased muscle production of immunoproteasome. In vitro analyses using bone marrow-derived Mø of BlAJ mice show that immunoproteasome inhibition results in C3aR1 and C5aR1 downregulation and upregulation of M2-associated signaling. Administration of immunoproteasome inhibitor ONX-0914 to BlAJ mice rescues muscle function by reducing muscle infiltrates and fibro-adipogenesis. These findings reveal an important role of immunoproteasome in the progression of muscular dystrophy in BlAJ mouse and suggest that inhibition of immunoproteasome may produce therapeutic benefit in dysferlinopathy. Nature Publishing Group UK 2022-11-19 /pmc/articles/PMC9675822/ /pubmed/36402750 http://dx.doi.org/10.1038/s41419-022-05416-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Farini, A.
Tripodi, L.
Villa, C.
Napolitano, F.
Strati, F.
Molinaro, D.
Facciotti, F.
Cassani, B.
Torrente, Y.
Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice
title Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice
title_full Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice
title_fullStr Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice
title_full_unstemmed Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice
title_short Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice
title_sort inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient blaj mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675822/
https://www.ncbi.nlm.nih.gov/pubmed/36402750
http://dx.doi.org/10.1038/s41419-022-05416-1
work_keys_str_mv AT farinia inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice
AT tripodil inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice
AT villac inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice
AT napolitanof inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice
AT stratif inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice
AT molinarod inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice
AT facciottif inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice
AT cassanib inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice
AT torrentey inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice